Table 3.
Baseline characteristics
| General information | Subcohort(n = 1208) | CVD cases(n = 515) |
|---|---|---|
| Male, [%] | 58 | 65 |
| Age, y [SD] | 61.5 (40–96) | 67.9 (40–96) |
| Follow-up, days [SD] | 620 (1–1460) | 322 (1–1369) |
| Academic referral centre, [%] | 77 | 77 |
| Use of contrast agent [%] | 68 | 67 |
| Image quality, [%] | ||
| Good | 72 | 74 |
| Moderate | 24 | 24 |
| Bad | 3 | 2 |
| Indication category, [%] | ||
| (1)Lung disease | 37 | 47 |
| (3)Haematological malignancies | 11 | 6 |
| (4)Mediastinal abnormalities | 11 | 8 |
| (5)Ruled-out pulmonary malignancya | 24 | 21 |
| (6)Pulmonary emboli | 6 | 8 |
| (8)Other indications | 11 | 10 |
| Thoracic aorta calcification | ||
| None | 39 | 18 |
| Mild | 30 | 25 |
| Moderate | 19 | 33 |
| Severe | 12 | 24 |
| Coronary arteries calcification | ||
| None | 33 | 12 |
| Mild | 24 | 22 |
| Moderate | 25 | 29 |
| Severe | 18 | 37 |
| Aortic valve calcification, [%] | ||
| None | 72 | 53 |
| Calcification on one leaflet | 16 | 20 |
| Calcification on two or three leaflets | 11 | 27 |
| Mitral valve calcification, [%] | ||
| None | 91 | 82 |
| Calcification on one leaflet | 7 | 14 |
| Calcification on two leaflets | 2 | 4 |
| Presence of annular calcification mitral valve [%] | 12 | 20 |
aPulmonary mass, which is proven to be non-malignant
Values are means [SD] or proportions